RepliCel Life Sciences Debt/Equity
What is the Debt/Equity of RepliCel Life Sciences?
The Debt/Equity of RepliCel Life Sciences, Inc. is -1.06
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with debt/equity similar to RepliCel Life Sciences
- Revlon has Debt/Equity of -1.07
- CaNickel Mining has Debt/Equity of -1.07
- Generation Asia I Acquisition L has Debt/Equity of -1.07
- Tymbal Resources has Debt/Equity of -1.07
- Alps Industries has Debt/Equity of -1.06
- Direct Selling Acquisition has Debt/Equity of -1.06
- RepliCel Life Sciences has Debt/Equity of -1.06
- Aban Offshore has Debt/Equity of -1.06
- Aban Offshore has Debt/Equity of -1.06
- Grand Vision Media Plc has Debt/Equity of -1.06
- Sun Cheong Creative Development has Debt/Equity of -1.06
- RosCan Gold has Debt/Equity of -1.06
- TLG Acquisition One has Debt/Equity of -1.06